Liver function in early Lyme disease.

To evaluate the frequency, pattern, and severity of liver function test abnormalities in patients with Lyme disease associated with erythema migrans (EM), 115 individuals with no other identifiable cause for liver function test abnormalities who presented with EM between July 1990 and September 1993 were prospectively evaluated. For individuals with abnormal liver function tests, common causes of hepatitis, including hepatitis A, B, and C, were excluded. A local control group was used for comparison. Forty-six (40%) patients had at least one liver test abnormality, and 31 (27%) had more than 1 abnormality compared with 19 (19%) and 4 (4%) of controls, respectively (P < .01 for each comparison). gamma-Glutamyl transpeptidase (28%) and alanine transaminase (ALT) (27%) were the most frequently elevated liver function tests among Lyme disease patients. Anorexia, nausea, or vomiting was reported by 30% of patients, but did not occur more frequently in patients with elevated liver function tests compared with those with normal values. Patients with early disseminated Lyme disease were more likely to have elevated liver function studies (66%) compared with patients with localized disease (34%) (P = .002). After antibiotic treatment, elevated liver function tests improved or resolved in most patients. Liver function test abnormalities are common in patients with EM but were mild, most often not associated with symptoms, and improved or resolved by 3 weeks after the onset of antibiotic therapy in most patients.

Tuberculin skin test conversion in hospital employees vaccinated with bacille Calmette-Guérin: recent Mycobacterium tuberculosis infection or booster effect?

OBJECTIVE: A rise in the incidence of purified protein derivative (PPD) skin test conversions among employees at our medical center between 1991 and 1993 prompted an examination of factors associated with PPD skin test conversion. We focused on the effect of bacille Calmette-Guérin (BCG) vaccination on PPD skin test conversion because of changes in employee health service policies in 1990 regarding testing of persons who had received BCG vaccination. METHODS: The study took place in a university teaching hospital employee health service. Charts of employees who had PPD skin test conversion (> 10 mm increase in induration of the PPD response within 2 years if younger than 35 years of age or > 15 mm if older than 35 years of age) between 1988 and 1993 were reviewed for factors that could have influenced PPD skin test conversion and compared with data from 271 randomly selected charts of employees who underwent annual employee assessments in 1993 but did not have PPD skin test conversion. RESULTS: PPD skin test conversions rose from 0.06% (1/1604) to 1.3% (22/1760; p = 0.000001) in employees tested between 1988 and 1993. Of 41 persons with PPD skin test conversion between 1991 and 1993, 29 (71%) had received BCG vaccination. Only 21% of control subjects (56/271) had received BCG vaccination (p < 0.000001 for comparison of BCG vaccination among those with PPD skin test conversion with that among control subjects). When BCG recipients were not included as having PPD skin test conversion, there was no significant increase in PPD skin test conversions. Twenty-three BCG recipients had PPD skin test conversion on their second PPD skin tests. CONCLUSION: A large proportion of PPD skin test conversions at hospitals that employ large numbers of health care workers who have received BCG vaccination may not represent recently acquired tuberculosis. Rather, these conversions may be effects of previous BCG vaccination. Two-step initial PPD skin testing may help to eliminate nearly 80% of such false-positive conversions.